AMIX AUTONOMIX MEDICAL INC

Autonomix Medical, Inc. Treats First Patient in Follow-On Market Expansion Phase (“PoC 2”) of Proof-of-Concept Human Clinical Study

Autonomix Medical, Inc. Treats First Patient in Follow-On Market Expansion Phase (“PoC 2”) of Proof-of-Concept Human Clinical Study

Expansion of study into additional indications doubles the potential addressable market beyond pancreatic cancer pain

PoC 2 phase builds on early success and positive results demonstrated in PoC 1 in patients with severe pancreatic cancer pain, supporting multi-indication growth strategy

THE WOODLANDS, TX, June 30, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced the first patient has been enrolled and treated in the follow-on phase to its proof-of-concept human clinical trial (“PoC 2”) evaluating the safety and effectiveness of delivering transvascular energy to ablate relevant problematic nerves and mitigate cancer pain.

“We’re executing on a bold vision to expand the reach of our technology beyond pancreatic cancer pain and into a broader range of high-need visceral cancer indications,” said Brad Hauser, CEO of Autonomix. “The start of patient treatment in our PoC 2 study represents a major milestone that reinforces our momentum and marks a critical step toward unlocking substantial clinical and commercial potential. We believe this expansion strengthens our value proposition and positions us to deliver meaningful impact for patients while creating long-term value for shareholders. We look forward to sharing further updates as clinical data become available.”

As previously announced, based on the positive results demonstrated in the initial phase of the Company’s first-in-human proof-of-concept study (“PoC 1”) in patients with severe pancreatic cancer pain, Autonomix has initiated a follow-on PoC 2 phase in a market expansion opportunity, which doubles the potential addressable market beyond pancreatic cancer pain by evaluating additional visceral cancers that signal pain through the Celiac Plexus and earlier stage pancreatic cancers with moderate to severe pain.

Autonomix’s technology constitutes a platform with the potential to address dozens of indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. The PoC 2 phase will provide a concentrated focus on interventional cancer pain management applications like pancreatic, gall bladder, liver, and bile duct, with potential further expansion in oncology, gastroenterology, and other sectors where the Company has established key opinion leader relationships and emerging preclinical evidence.

About Autonomix Medical, Inc.

Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.

We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.

For more information, visit and connect with the Company on , , and .

Forward Looking Statements

Some of the statements in this release are “forward-looking statements,” which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the results of the PoC 2 phase of the trial. Such forward-looking statements can be identified by the use of words such as “should,” “might,” “may,” “intends,” “anticipates,” “believes,” “estimates,” “projects,” “forecasts,” “expects,” “plans,” and “proposes.”

Although Autonomix believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading “Risk Factors” and elsewhere in the Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (“SEC”) on May 31, 2025 and in other filings made by us from time to time with the SEC. Forward-looking statements speak only as of the date of the document in which they are contained and Autonomix does not undertake any duty to update any forward-looking statements except as may be required by law.

Investor and Media Contact

JTC Team, LLC

Jenene Thomas

908.824.0775

 



EN
30/06/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on AUTONOMIX MEDICAL INC

 PRESS RELEASE

Autonomix Medical, Inc. Treats First Patient in Follow-On Market Expan...

Autonomix Medical, Inc. Treats First Patient in Follow-On Market Expansion Phase (“PoC 2”) of Proof-of-Concept Human Clinical Study Expansion of study into additional indications doubles the potential addressable market beyond pancreatic cancer pain PoC 2 phase builds on early success and positive results demonstrated in PoC 1 in patients with severe pancreatic cancer pain, supporting multi-indication growth strategy THE WOODLANDS, TX, June 30, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies t...

 PRESS RELEASE

Autonomix Medical, Inc. Granted New U.S. Patent for Innovative Cathete...

Autonomix Medical, Inc. Granted New U.S. Patent for Innovative Catheter-Based Platform Technology Patent supports the Company’s broader mission to advance minimally invasive, nerve-focused treatments across high-need indications Strengthens strategic position in a multi-billion-dollar market opportunity and expands Autonomix’s growing global IP portfolio with over 80 issued patents THE WOODLANDS, TX, June 27, 2025 (GLOBE NEWSWIRE) --  (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the U...

 PRESS RELEASE

Autonomix Medical, Inc. Granted Approval to Expand Proof-of-Concept Hu...

Autonomix Medical, Inc. Granted Approval to Expand Proof-of-Concept Human Clinical Study, Doubling Potential Addressable Market Beyond Pancreatic Cancer Pain Follow-on study (“PoC 2”) builds on initial success in pancreatic cancer pain  Ethics committee authorization supports platform expansion into visceral cancer pain for proprietary ablation technology Expansion supports Autonomix’s strategy to build long-term value through multi-indication growth Patient enrollment expected to begin in June 2025 THE WOODLANDS, TX, June 05, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: AMIX) (“Autonomix” or ...

 PRESS RELEASE

Autonomix Medical, Inc. Granted Key U.S. Patent for Innovative Cathete...

Autonomix Medical, Inc. Granted Key U.S. Patent for Innovative Catheter-Based Platform Technology Patent strengthens Autonomix’s intellectual property position in the nerve-mapping and denervation space, supporting the Company’s broader mission to advance minimally invasive, nerve-focused therapeutics Company continues to expand its growing global patent portfolio with over 80 issued patents and 40 pending patent applications THE WOODLANDS, TX, May 15, 2025 (GLOBE NEWSWIRE) --  (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerv...

 PRESS RELEASE

Autonomix CEO Brad Hauser to Present at Virtual Investor’s Closing Bel...

Autonomix CEO Brad Hauser to Present at Virtual Investor’s Closing Bell Event Live webcast followed by an interactive Q&A session on Thursday, May 22nd at 4:00 PM ET Access the event THE WOODLANDS, TX, May 14, 2025 (GLOBE NEWSWIRE) --  (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing precision nerve-targeted treatments, today announced it will participate in the on Thursday, May 22, 2025 at 4:00 PM ET. As part of the event, of Autonomix, will provide a corporate overview and discuss the Company’s first-in-class platform system technology,...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch